Double-stranded nucleotide compound for immune disease and use thereof

HK40137766APending Publication Date: 2026-09-18VISIRNA THERAPEUTICS (SUZHOU) CO LTD

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: HK62026125363
Authority / Receiving Office: HK · HK
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-05-30
Filing Date: 2026-06-26
Publication Date: 2026-09-18
Estimated Expiration: 2044-05-30

Application Information

Patent Timeline

30 May 2024

Priority

26 Jun 2026

Application

HK62026125363

18 Sep 2026

Publication

HK40137766A

IPC: C12N15/113; A61K31/713

Inventors: HE, QIONGER; WANG, MINGJIE

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Smart Images

Figure 00000033_0000
Figure 00000033_0001
Figure 00000034_0000

Patent Text Reader

Abstract

The invention provides a small interfering RNA (Ribonucleic Acid) for inhibiting expression of a complement factor B (CFB) and application of the small interfering RNA to preparation of a medicine for treating diseases related to expression of the complement factor B.

Need to check novelty before this filing date? Find Prior Art

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480036556.8 (22) Application Date 2024.05.31 (66) Domestic Priority Data 202310652201.9 2023.06.02 CN 202410693481.2 2024.05.30 CN (85) PCT International Application Entering National Phase Date 2025.12.01 (86) PCT International Application Application Data PCT / CN2024 / 096814 2024.05.31 (87) PCT International Application Publication Data WO2024 / 245424 ZH 2024.12.05 (71) Applicant Viagene Biotechnology (Suzhou) Co., Ltd. Address 215028 Unit 401, Building 5, Block B, Phase III, Biomedical Industrial Park, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province (72) Inventors: He Qionger, Wang Mingjie, Zou Xiaoming, Yang Hongkuan, Yu Weiwei (74) Patent Agency: Beijing Junhe Law Firm 11517 Patent Attorneys: Wu Yu, Luo Yiyang (51) Int.Cl. C12N 15 / 113 (2006.01) A61K 31 / 713 (2006.01) (54) Invention Title: A Double-Stranded Nucleotide Compound for Immune Diseases and Its Application (57) Abstract: A small interfering RNA that inhibits the expression of complement factor B (CFB) and its use in the preparation and treatment of drugs for diseases related to complement factor B expression. CN 121311588 A 2026.01.09 CN 1 21 31 15 88 A